
2020-08-20 17:12:41
PhillipCapital remains positive on Hyphens Pharma following 'intact' underlying 1H20 revenue growth
PhillipCapital analyst Tay Wee Kuang has maintained his “accumulate” call on catalist-listed pharmaceutical distributor Hyphens Pharma with an increased target price of 49.5 cents from 43.5 cents previously following the company’s 2Q20/1H20 results. On August 13, Hyphens Pharma posted a 32% y-...